Span Divergent Limited
BSE: SDL · Pharmaceuticals · sector
₹24.24BSE close 2026-10-26
Key numbers
Market cap₹11 cr
Price₹24.24
52w high / low₹51 / ₹21
P/E4.0xSector median 27.9x
P/B0.8xSector median 2.9x
Book value₹31.5
Dividend yield–Sector median 0.48%
ROE-51.8%Sector median 11.7%
ROCE-14.0%Sector median 12.3%
OPM-16.6%Sector median 14.0%
Debt / equity0.48xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover-6.3x
Current ratio1.10x
Sales growth 3y+106.4%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹12 cr vs borrowings ₹7 cr (FY26): cash is higher (net cash).
- Operating profit covered interest -6.3x in the last 12 months.
- Net loss in 6 of the last 6 quarters.
- No dividend in the last 5 financial years.
- Price ₹24.24 on 2026-10-26: -52.9% from the 52-week high, +18.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹46.66 · low ₹19.52
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 8 | 4 | 5 | 1 |
| EBITDA | -1 | -0 | 0 | -1 | -1 | -1 |
| OPM % | -170.9% | -43.9% | 0.0% | -24.3% | -18.3% | -102.9% |
| Other income | 0 | 1 | 0 | 0 | 0 | 0 |
| Net profit | -1 | -0 | -0 | -1 | -1 | -1 |
| EPS (₹) | 1.87 | 0.31 | 0.34 | 2.08 | 2.02 | 1.64 |
| Revenue YoY | +743.6% | -4.7% | ||||
| Profit YoY | – | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2 | 2 | 2 | 9 | 17 | 17 |
| EBITDA | -9 | -4 | 0 | -1 | -3 | -3 |
| Net profit | -8 | -3 | 2 | -1 | -2 | -3 |
| EPS (₹) | -14.20 | -6.11 | 2.76 | 2.33 | 5.38 | 6.08 |
| Revenue growth | 0.0% | -2.0% | +366.7% | +92.2% | – | |
| Profit growth | – | – | -160.9% | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +106.4% | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -13.7% (2y) | -10.7% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | -3 | 15 |
| Borrowings | 8 | 7 |
| Cash & equivalents | 7 | 12 |
| Total assets | 23 | 29 |
| Fixed assets | 10 | 9 |
| Capital work in progress | 0 | 0 |
| Investments | 0 | 0 |
| Receivables | 1 | 2 |
| Inventory | 1 | 2 |
| Payables | 3 | 6 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 2 | 0 |
| Cash from investing | -1 | 2 |
| Cash from financing | -1 | 4 |
| Capex | 0 | 0 |
| Free cash flow | 2 | -0 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 32.7% | -16.8% |
| ROCE % | -8.6% | -11.2% |
| Debtor days | 56 | 33 |
| Inventory days | 123 | 40 |
| Payable days | 426 | 136 |
| Cash conversion cycle (days) | -247 | -63 |
| Working capital days | -632 | 36 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SDL | ₹11 cr | 4.0x | 0.8x | -51.8% | -14.0% | -16.6% | +106.4% | – |
Business segments (2026-06-30)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Trading | ₹1 cr | 65.5% | ₹-0 cr | -29.7% |
| Cashew processing | ₹0 cr | 34.5% | ₹-1 cr | -231.4% |
| Tissu Culture | ₹0 cr | – | ₹0 cr | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2013-07-16 | Dividend | Dividend Rs 0.5 |
| 2011-07-26 | Dividend | Dividend Rs 1.0 |
| 2010-06-18 | Dividend | Dividend Rs 2.5 |
| 2008-08-08 | Dividend | Dividend Rs 2.0 |
| 2007-08-10 | Dividend | Dividend Rs 1.8 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SDL |
| BSE code | 524727 |
| ISIN | INE004E01016 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.